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TO THE EDITOR
Extracorporeal photopheresis (ECP) is
effective for patients with leukemic
cutaneous T-cell lymphoma (L-CTCL),
including Se´zary syndrome and mycosis
fungoides with blood involvement
(Edelson et al., 1987), and graft-versus-
host disease (GVHD)(Couriel et al.,
2006), but whether its mechanism(s) of
action in these diseases is/are identical
or different is unclear. The anti-tumor
immunity mediated by cytotoxic
T lymphocytes (CTLs) is thought to
underlie the efficacy of ECP in L-CTCL
(Edelson, 2001) while the immune
tolerance mediated by regulatory
T cells (Tregs) is claimed to be beneficial
in GVHD (Hippen et al., 2011). Den-
dritic cells (DCs) are key antigen-presen-
ting cells required for inducing immune
response or peripheral tolerance. Berger
et al. (2001) reported that mono-
cytes differentiated to DCs during ECP.
In GVHD mice models, the suppressive
effects of antigen-specific Tregs were
lost when removing CD11cþ cells, indi-
cating a key role of DCs in the Tregs
suppression (Maeda et al., 2005). There-
fore, we hypothesized that the para-
doxical immunologic effects of ECP in
L-CTCL and GVHD might be explained
if ECP modulates different DC subpopu-
lations in both. To explore the effect
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Figure 1. Flow cytometry analysis of LinHLA-DRþCD11cþ myeloid dentritic cells (mDCs) and LinHLA-DRþCD123þ plasmacytoid DCs (pDCs) in
normal donors, graft-versus-host disease (GVHD), and leukemic cutaneous T-cell lymphoma (L-CTCL) patients at baseline. (a) Peripheral blood mononuclear
cells (PBMCs) from normal donors (ND), GVHD, and L-CTCL patients were analyzed by flow cytometry for LinHLA-DRþCD11cþ mDCs (upper panel,
circled portions) and LinHLA-DRþCD123þ pDCs (lower panel, circled portions). The representative flow plots from ND, GVHD, and L-CTCL patients with
normal (L-CTCL-normal) and low (L-CTCL-low) counts are presented. The % of (b) mDCs and (c) pDCs in PBMCs from ND, GVHD, and L-CTCL patients
(mean±SD). The (d) mDC/pDC and (e) pDC/mDC ratios in ND, GVHD, and L-CTCL patients. The HLA-DR expression on (f) mDCs and on (g) pDCs in ND,
GVHD, and L-CTCL patients. MFI, mean fluorescence intensity. Student’s t-test, *Po0.05; **Po0.01.
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of ECP on DCs in vivo, we exa-
mined circulating CD11cþ myeloid
DCs (mDCs) and CD123þ plasma-
cytoid DCs (pDCs) by flow cytometry
in L-CTCL and GVHD patients over ECP
treatments. This is, to our knowledge, a
previously unreported study to monitor
DC kinetic changes in vivo over ECP
treatment in L-CTCL and GVHD
patients in parallel. It provides insights
into how ECP could effectively treat two
immunological diseases with nearly
opposite immunopathogenesis.
The demographics of 18 L-CTCL
patients are summarized in Supplemen-
tary Table S1 online. Patients received
an average of 9.5 (6B13) cycles of ECP
treatment over a 6-month period. After
6 months, 12 of 18 (66.7%) had clinical
responses determined by changes in
modified severity weighted assessment
tool (Supplementary Figure S1a online)
and circulating tumor cells (Supplemen-
tary Figure S1b online). Eleven GVHD
patients on study developed acute and
chronic GVHD after matched non-
ablative stem cell transplantation as
summarized in Supplementary Table
S2 online. GVHD patients received an
average of 14.6 to 29.9 cycles of ECP
over a 3- to 6-month period. After 3 to
6 months of treatment, 6 of 11 patients
achieved skin and/or other organ
improvement.
Before ECP, GVHD patients had low
levels of mDCs and pDCs, but L-CTCL
patients had heterogeneous levels
(Figure 1a–c, Supplementary Table S3
online). Twelve of 18 L-CTCL patients
had lower than normal mDCs, and 10 of
18 had lower than normal pDCs. One-
third of L-CTCL patients (5/18, mDCs;
7/18, pDCs) had normal DC levels. After
ECP, increasing mDCs and pDCs were
noted in six GVHD patients, especially
pDCs (Figure 2a–c). The average of
mDC numbers in L-CTCL patients were
increased after 6 months (Figure 2d and
e) but not pDCs (Figure 2d and f).
Increased mDCs were present in 8 of
12 L-CTCL patients with low baseline
mDCs, and also in 4 of 5 with normal
baseline mDCs, as well as 1 with high
baseline mDCs (Shiue et al., 2012). In
contrast, only 5 of 10 L-CTCL patients
with low baseline pDCs showed increa-
sed pDCs after ECP. Four of seven
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Figure 2. Effect of extracorporeal photopheresis (ECP) on LinHLA-DRþCD11cþ myeloid dentritic cells (mDCs) and LinHLA-DRþCD123þ plasmacytoid
DCs (pDCs) in graft-versus-host disease (GVHD) and leukemic cutaneous T-cell lymphoma (L-CTCL) patients. (a) The representative flow plots from
GVHD patient no. 3 for LinHLA-DRþCD11cþ mDCs (upper panel, circled portions) and LinHLA-DRþCD123þ pDCs (lower panel, circled portions)
are presented. The % of (b) mDCs and (c) pDCs in GVHD patients at baseline (BL), day 2, 1 month, 3/4months, and 6/7 months after ECP. (d) The representative
flow plots from L-CTCL patient no. 11 are presented. The % of (e) mDCs and (f) pDCs in L-CTCL patients at BL, day 2, 1 month, 3/4 months, 6/7months, and
9–12 months after ECP. The dotted lines are linear trend lines. Linear mixed model analysis, *Po0.05. The average (g) mDC/pDC and (h) pDC/mDC ratios in
L-CTCL (-K-) versus GVHD (y’y) at BL day 2, 1 month, 3/4 months, 6/7 months, and 9–12 months after ECP.
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L-CTCL patients with normal and one
with high baseline pDCs showed
decreased pDC numbers over therapy.
We noted that ratios of mDCs and
pDCs in GVHD and L-CTCL patients
are favorably altered after ECP. GVHD
patients possessed high mDC/pDC
or low pDC/mDC ratios at base-
line (Figure 1d and e). Instead, 15 of
18 L-CTCL patients had normal ratios
of mDC/pDC (Supplementary Table S3
online). After ECP, GVHD patients
showed a continuous decrease in
mDC/pDC ratios (Figure 2g) or increase
in pDC/mDC ratios (Figure 2h). The
average mDC/pDC ratios in L-CTCL
patients were significantly increased
after 3 and 6 months (Figure 2g). These
trends continued up to 9B12 months in
four patients who remained on therapy.
As expected, pDC/mDC ratios decrea-
sed in L-CTCL patients (Figure 2h).
In addition, we found that HLA-DR
expression on mDCs and pDCs was
increased in L-CTCL patients responding
to ECP. At baseline, HLA-DR expression
on mDCs was low in both GVHD and
L-CTCL patients (Figure 1f). Sixteen of
18 L-CTCL patients had lower than
normal HLA-DR expression on mDCs
(Supplementary Table S3 online), and
half of L-CTCL patients had low HLA-
DR expression on pDCs (Supplementary
Table S3 online). After ECP treatment,
levels of HLA-DR on mDCs and pDCs
remained unchanged in GVHD patients,
but upregulated in L-CTCL patients. Ten
of 16 L-CTCL patients with low baseline
HLA-DR on mDCs had higher levels
at after 6 months, and 8 of 10 were
responders. In contrast, three of six
nonresponders had decreased HLA-DR
levels on mDCs. After ECP, seven of
nine with low baseline HLA-DR on
pDCs also had increased levels, and
six of seven were responders, but four
of six nonresponders had decreased
HLA-DR expression.
In summary, the findings of increased
mDC populations, increased mDC/pDC
ratios, and upregulation of HLA-DR
expression following ECP in two-thirds
of L-CTCL patients suggest that ECP
treatment is associated with favorable
mDC modulation. On the other hand,
the findings of increased pDC popula-
tions and pDC/mDC ratios in GVHD
patients suggest that ECP treatment
is associated with favorable pDC mod-
ulation. We conclude that the augmen-
tation of blood DCs and balancing of
DCs toward a more normal status by
ECP may underlie its efficacy in both
L-CTCL and GVHD patients; however,
we cannot exclude a role of concomi-
tant therapies.
It is known that mDCs polarize naı¨ve
T cells toward a Th1 phenotype, where-
as pDCs result in a Th2/Treg pheno-
type with IL-3 stimulation and ICOSL
expression (Kadowaki, 2007). Clinical
improvements after ECP in CTCL
patients are associated with a shift
from Th2 to IL-12/Th1 phenotype
(Di Renzo et al., 1997) while a shift
from Th1 to Th2 by ECP was observed
in GVHD (Gorgun et al., 2002). We
therefore postulate that in L-CTCL, ECP
treatment not only induces apoptosis of
malignant Th2/Treg cells but also recruits
more mDCs, creates a pro-inflammatory
environment for DCs to activate, and
further stimulates Th1/CTLs and immune
responses (Ni et al., 2008). In contrast,
in GVHD, ECP induces apoptosis of
pathologic Th1 cells, and recruits more
pDCs favoring the expansion of Th2/
Tregs cells, which could lead to T-cell
anergy or tolerance to transplants or
auto tissues.
The study was approved by the
University of Texas MD Anderson
Cancer Center Institutional Review
Board and conducted according to
Declaration of Helsinki Principles.
Patients gave written informed consent.
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